Excellent Science for New Therapies

Chronic inflammmation, triggered by dysfunctions on the boundary surfaces of the body’s organs and their interaction with the environment, represents a central challenge for modern medicine. It is considered to be the cause of many chronic diseases, which have been steadily increasing in recent decades – especially in western industrialized countries. The goal of the Cluster of Excellence in Inflammation Research is to decode the molecular basis of chronic inflammatory diseases, as well as the complete identification of metabolic and signaling pathways as an approach to therapies and prevention. The unforeseen complexity and the breadth of possible triggers of inflammatory diseases require new scientific structures and practices. In the Excellence Cluster, key elements of the origins of inflammation will be examined in detail on genetic, genomic and functional levels. The cluster is a joint venture of Kiel University and the University of Lübeck, together with the Schleswig-Holstein University Medical Center, the Leibniz Research Center Borstel, the Max Planck Institute for Evolutionary Biology, Plön, and the Muthesius Academy of Fine Arts and Design in Kiel. More: www.inflammation-qt-interfaces.de
Picture: David Ellinghaus

More News

The large and lively “HALRIC family” gathered in Lund in February to recap the three amazing years of the project and look ahead to the future. (Photo: HALRIC)
The large and lively “HALRIC family” gathered in Lund in February to recap the three amazing years of the project and look ahead to the future. (Photo: HALRIC)

HALRIC Strengthens Life Science Connections in Northern Europe

After three years, Life Science Nord has issued a positive assessment of the Interreg project HALRIC – Hanseatic Life Science Research Infrastructure Consortium. The project’s ...

Read more …
Dr. Fernando Delgado (CTO), Dr. Michael Hartung (CPO), Alexander Zahn (CEO), and Prof. Dr. Jan Baumbach (CSO) (from left) founded the company in Hamburg in 2025. (Photo: Galagos)
Dr. Fernando Delgado (CTO), Dr. Michael Hartung (CPO), Alexander Zahn (CEO), and Prof. Dr. Jan Baumbach (CSO) (from left) founded the company in Hamburg in 2025. (Photo: Galagos)

#NEWatLSN: Galagos

We are delighted to welcome Galagos as a new member of Life Science Nord e.V.! The founding team answered questions about the company’s initial goals, ...

Read more …
The meetings brought together senior representatives from the European Commission and multiple Member States. (Picture: HALRIC)
The meetings brought together senior representatives from the European Commission and multiple Member States. (Picture: HALRIC)

HALRIC in Brussels

Through direct dialogue with the European Commission and Member States, HALRIC’s Brussels discussions showed how cross-border life science collaboration can unlock efficiency, strengthen European competitiveness, ...

Read more …